SCHEMBL362230

SCHEMBL362230

COC(=O)c1cnc(N)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 5/20 0.48
KDR P35968 5/20 0.48
MAPK1 P28482 3/20 0.46
ATM Q13315 2/20 0.46
KDM4E B2RXH2 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
P2RY12 Q9H244 1/20 0.43
SCN9A Q15858 1/20 0.43
SCN2A Q99250 1/20 0.43
SCN3A Q9NY46 1/20 0.43
SCN10A Q9Y5Y9 1/20 0.43
CYP2D6 P10635 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
PSMD14 O00487 1/20 0.42
MAPT P10636 2/20 0.42
POLB P06746 1/20 0.42
GAA P10253 2/20 0.41
S1PR4 O95977 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31108808 1.00 PDGFRB (0.48) PDGFRBKDRMAPK1ATMKDM4E
SCHEMBL31705858 0.82 KDM4E (0.51) PDGFRBKDRMAPK1ATMKDM4E
SCHEMBL29726958 0.82 ALDH1A1 (0.51) MAPK1ATMKDM4EL3MBTL1P2RY12
SCHEMBL473919 0.82 ALDH1A1 (0.51) MAPK1ATMKDM4EL3MBTL1P2RY12
SCHEMBL41129 0.82 KDM4E (0.51) PDGFRBKDRMAPK1ATMKDM4E
SCHEMBL5320922 0.82 CYP2C9 (0.50) MAPK1L3MBTL1P2RY12ALDH1A1
SCHEMBL23774958 0.82 PSMD14 (0.43) PDGFRBKDRMAPK1ATMKDM4E
SCHEMBL16421752 0.81 ATM (0.51) PDGFRBKDRMAPK1ATMKDM4E
SCHEMBL3655489 0.81 MAPK1 (0.47) MAPK1ATMKDM4EL3MBTL1P2RY12
SCHEMBL198706 0.81 MAPK1 (0.47) MAPK1ATMKDM4EL3MBTL1P2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230087118-A1 IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE BIOGEN MA INC. 2023-03-23 US disclosed
EP-2593451-B1 SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES BAYER IP GMBH (DE) 2015-08-19 EP disclosed
US-8975265-B2 Substituted imidazo[1,2-a]pyrimidines and —pyridines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-03-10 US disclosed
US-20130190332-A1 Substituted Imidazo[1,2-a]pyrimidines and -pyridines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-07-25 US disclosed
EP-2593451-A2 SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES Bayer Intellectual Property GmbH (DE) 2013-05-22 EP disclosed
WO-2012007345-A2 SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230087118-A1 IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE IRAK4, IRAK2, IRAK1 PDGFRB 490/4885KDR 188/4885MAPK1 308/4885
US-20130190332-A1 Substituted Imidazo[1,2-a]pyrimidines and -pyridines PIK3CA, PIK3CD, PIK3CB PDGFRB 113/4885KDR 223/4885MAPK1 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.